Astatine-211 (At-211) is a promising alpha emitting radioisotope for cancer therapy, but its short 7.2-hour half-life means that it must be handled quickly to minimize losses due to radioactive decay. In this research, scientists designed and tested an automated device for producing At-211 that improves production time and efficiency. The device also minimizes the dose of radioactivity to production staff and reduces the time needed to prepare samples for shipment.
